![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00638742 |
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
Condition | Intervention | Phase |
---|---|---|
Glaucoma Ocular Hypertension |
Drug: latanoprost |
Phase I |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Single Group Assignment, Pharmacokinetics Study |
Official Title: | A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%. |
Estimated Enrollment: | 30 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: latanoprost
latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
United States, California | |
Pfizer Investigational Site | Active, not recruiting |
Artesia, California, United States, 90701 | |
United States, Georgia | |
Pfizer Investigational Site | Completed |
Atlanta, Georgia, United States, 30339 | |
Pfizer Investigational Site | Completed |
Atlanta, Georgia, United States, 30342 | |
United States, Massachusetts | |
Pfizer Investigational Site | Completed |
North Dartmouth, Massachusetts, United States, 02747 | |
United States, Michigan | |
Pfizer Investigational Site | Recruiting |
Ann Arbor, Michigan, United States, 48105 | |
United States, Minnesota | |
Pfizer Investigational Site | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Pfizer Investigational Site | Not yet recruiting |
New York, New York, United States, 10032 | |
United States, North Carolina | |
Pfizer Investigational Site | Active, not recruiting |
Durham, North Carolina, United States, 27705 | |
United States, South Carolina | |
Pfizer Investigational Site | Recruiting |
Charleston, South Carolina, United States, 29425 | |
Denmark | |
Pfizer Investigational Site | Recruiting |
Koebenhavn OE, Denmark, 2100 | |
Greece | |
Pfizer Investigational Site | Not yet recruiting |
Athens, Greece, 115 27 | |
Italy | |
Pfizer Investigational Site | Completed |
Catania, Italy, 95123 | |
Portugal | |
Pfizer Investigational Site | Completed |
Lisboa, Portugal, 1169-097 | |
Pfizer Investigational Site | Completed |
Coimbra, Portugal, 3000-548 | |
South Africa | |
Pfizer Investigational Site | Recruiting |
Mayfair West, South Africa, 2109 | |
Spain | |
Pfizer Investigational Site | Recruiting |
MADRID, Spain, 28040 | |
Pfizer Investigational Site | Active, not recruiting |
MADRID, Spain, 28046 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A6111139 |
Study First Received: | March 12, 2008 |
Last Updated: | April 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00638742 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Latanoprost Pediatrics Pharmacokinetics Safety |
Glaucoma Eye Diseases Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Latanoprost Hypertension Ocular Hypertension |
Glaucoma Therapeutic Uses Eye Diseases Vascular Diseases Cardiovascular Diseases Cardiovascular Agents |
Antihypertensive Agents Latanoprost Pharmacologic Actions Ocular Hypertension Hypertension |